In patients with left main coronary artery (LMCA) stenosis, coronary artery bypass grafting (CABG) has been the standard therapy for several decades. However, some studies suggest that percutaneous coronary intervention (PCI) with drug-eluting stents may be an acceptable alternative.
C ompared with other sites, stenosis of the left main coronary artery (LMCA) is associated with a higher risk of mortality and myocardial injury owing to the larger amount of subtended myocardium. 1, 2 Coronary artery bypass grafting (CABG) has been the standard of care for LMCA stenosis for many years, but due to significant advances in device technology, increased operators' expertise, and availability of improved antithrombotic therapy, percutaneous coronary intervention (PCI) has emerged as a valid alternative technique in a significant proportion of patients. [1] [2] [3] [4] Current European and American guidelines recommend both CABG and PCI for the treatment of LMCA stenosis in patients with overall low to intermediate complexity of coronary artery disease (CAD). 5, 6 Recently, however, primary analy- Previous meta-analyses did not include the EXCEL and NOBLE trials, [9] [10] [11] pooled both observational and randomized investigations, [9] [10] [11] combined patients receiving bare-metal stents and DESs, 9-12 assessed short-term and midterm outcomes, 9 used odds ratios or risk ratios for long-term outcomes, [10] [11] [12] and did not provide reconstruction of outcomes over time. [9] [10] [11] [12] Against this background, we carried out an updated meta-analysis of randomized clinical trials comparing DES-based PCI with CABG at long-term follow-up in patients with LMCA disease.
Methods
We conducted a frequentist, pairwise meta-analysis in accordance with PRISMA and Cochrane Collaboration recommendations. 13, 14 The PRISMA checklist is reported in eTable 1 in the Supplement. PubMed, Scopus, EMBASE, Web of Knowledge, and ScienceDirect databases were searched from December 18, 2001 , to February 1, 2017. Three of us (R.C., A.H.F., and J.W.) performed the search independently. After removal of duplicates, full-text screening was performed with resolution of divergences by consensus (D.G., R.C., A.H.F., and J.W.). Other details on the literature search, data extraction, and feasibility assessment are provided in the eMethods in the Supplement. The meta-analysis was approved by Deutsches Herzzentrum München.
Eligibility Criteria
We included investigations fulfilling all of the following criteria: (1) randomized clinical trial, (2) LMCA stenosis, (3) PCI vs CABG, (4) exclusive use of DESs, and (5) follow-up of 3 or more years. Trials reporting follow-up of less than 3 years were excluded to allow focus on long-term outcomes and limit the influence of early nonsignificant differences. 15 
End Points
The primary end point was a composite of all-cause death, myocardial infarction, or stroke at the longest available followup. The secondary end points were repeat revascularization, individual components of the primary end point, cardiac death, stent or graft occlusion, and a composite of all-cause death, myocardial infarction, stroke, or repeat revascularization at the longest available follow-up.
Statistical Analysis
Fixed-effect and random-effects models with inverse variance weighting using trial-level log hazard ratios (HRs) and corresponding SEs were applied. 16, 17 Trial-level and pooled estimates are reported as HR and 95% CI; risk distribution is presented by forest plots with weighting according to randomeffects models. 18 We assessed heterogeneity across trials using between-study variance τ 2 and I 2 statistics. 14, 16, 19 I 2 values less than 25% defined low heterogeneity; 25% to 50%, moderate heterogeneity; and greater than 50%, high heterogeneity. 14 Formal testing for uniform effect size across trials with significance set at P = .10 was performed. 16 7, 21 were synthesized by fixedeffect models. Testing for differences between the subgroups with significance set at P < .05 was performed. 16 Individual patient data reconstruction was performed by extrememagnification digitization of high-quality Kaplan-Meier curves. Retrieved spatial information, numbers at risk, and events for each time interval were used to run a validated algorithm.
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Reconstructed individual patient data were used for time-tofirst-event Kaplan-Meier analyses to describe distribution of events over time and define cumulative incidence at 5-year follow-up. In a 1-stage, individual patient data meta-analysis, a shared frailty model accounting for clustering of patients across
Key Points
Question Does percutaneous coronary intervention with drug-eluting stenting and coronary artery bypass grafting provide similar long-term safety and efficacy in patients presenting with significant coronary artery disease involving the left main coronary artery?
Findings In this systematic review and meta-analysis including 4394 patients, the 2 revascularization techniques provided similar long-term outcomes in terms of death, myocardial infarction, and stroke. Coronary artery bypass grafting was associated with a significant reduction in the risk of repeat revascularization.
Meaning Although patients undergoing coronary artery bypass grafting benefit from a lower risk of repeat revascularization, if a patient wishes to avoid the morbidity associated with surgical revascularization, percutaneous coronary intervention is a safe and effective alternative.
the original trials with semiparametric penalized likelihood estimation of the hazard function was fitted to obtain the combined HR. 23 All analyses were performed with R, version 3.3.1 (R Foundation).
Sensitivity and Subgroup Analyses
With respect to the primary end point, several analyses were conducted: (1) inspection of individual trial influence by removing each trial independently using a random-effects model, 24 (2) We assessed the influence of individual trials by influence analyses for each of the secondary end points and explored the effect of DES generation on repeat revascularization and the secondary composite end point. Finally, the SYNTAX trial has suggested that outcomes of patients undergoing PCI differ depending on the presence or absence of LMCA stenosis. 26 However, this trial had no power to detect differences between the 2 patterns of CAD, and no additional randomized trials have tested such a hypothesis. In a supplementary analysis, we compared safety outcomes between patients with and without LMCA stenosis.
Bias Assessment
Trial-level qualitative assessment was performed using the 7-domain Cochrane Collaboration tool. 14 The risk of bias was classified as high, unclear, or low. 14 We assessed the reliability of the results for each outcome according to Grading of Recommendations, Assessment, Development and Evaluation (GRADE). 
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Results
Characteristics of the Included Studies
Primary End Point
Percutaneous coronary intervention and CABG showed comparable outcomes ( Figure 1B) The comparison between trials of patients with LMCA stenosis and those of patients with MV-CAD without LMCA stenosis showed a significant difference regardless of the model applied (fixed effect: P = .01; random effects: P =.04) (Figure 2 ). Descriptive data of trials including patients with MV-CAD are reported in eTables 7-11 in the Supplement. After pooling all trials regardless of the anatomic pattern, at long-term followup, PCI was associated with a significantly increased risk (random effects: HR, 1.21; 95% CI, 1.02-1.45; P = .03).
Secondary End Points
With respect to repeat revascularization ( Figure 3A) , PCI was associated with a significantly higher risk compared with CABG (HR, 1.70; 95% CI, 1.42-2.05; P < .001). A total of 313 events occurred in the PCI group and 184 events occurred in the CABG group. Effect size was consistent across trials (I 2 = 0%, P = .87).
The grouping of trials according to DES generation did not significantly change the results ( Figure 3B ). The secondgeneration DES (HR, 1.63; 95% CI, 1.29-2.06; P < .001) and firstgeneration DES (HR, 1.83; 95% CI, 1.37-2.45; P < .001) groups showed a similar risk of repeat revascularization (P =.54).A t influence analysis, removal of each trial independently produced trivial changes ( Figure 3C ).
Regarding the secondary composite end point of allcause death, myocardial infarction, stroke, or repeat revascularization (eFigure 2, upper left in the Supplement), PCI was associated with an increased risk compared with CABG (HR, 1.27; 95% CI, 1.11-1.44; P < .001) without significant heterogeneity across included trials (I 2 = 0%, P = .58). Influence analysis showed consistent results (eFigure 2, lower left in the Supplement). First-and second-generation DES groups were associated with a similar risk increase (eFigure 2, right in the Supplement). Analyses of all-cause death, cardiac death, myocardial infarction, and stroke are shown in Figure 4 and eFigure 3 in the Supplement. There was a comparable risk of death between PCI and CABG in both all-cause (random effects: HR, 1.04; 95% CI, 0.81-1.33; P = .77) and cardiac (random effects: HR, 1.00; 95% CI, 0.72-1.39; P = .99), with mild heterogeneity and limited influence of individual trials. Although the risk of myocardial infarction was comparable between techniques (random effects: HR, 1.48; 95% CI, 0.85-2.58; P = .17), high heterogeneity was detected (I 2 =67 .4 %,P = .03) as a result of the risk increase in the PCI arm of the NOBLE trial 8 The comparison between trials of patients with LMCA stenosis and those of patients with MV-CAD without LMCA stenosis showed mixed results according to the model applied. Overall, there was a significant difference between the 2 groups of trials for the outcomes of all-cause death and myocardial infarction (eFigure 5 in the Supplement). Conversely, the 2 groups of trials seemed to be uniform in terms of stroke. Pooled estimates described a significant risk increase in all-cause death (random effects: HR, 1.21; 95% CI, 1.01-1.46; P = .04) and myocardial infarction (random effects: HR, 1.77; 95% CI, 1.20-2.59; P = .004) associated with PCI compared with CABG. Stroke showed a numerically reduced incidence after PCI compared with CABG (random effects: HR, 0.78; 95% CI, 0.49-1.26; P = .31).
Qualitative Review
Qualitative assessment of the trials showed an overall low risk of bias (eFigure 6 in the Supplement). According to GRADE, evidence quality with respect to the primary composite end point and repeat revascularization was high, evidence quality for death was moderate, and evidence quality for myocardial infarction, stroke, and stent or graft occlusion was low (eTable 12 in the Supplement). 
Discussion
The main finding of this meta-analysis is that, in patients with significant LMCA stenosis, both PCI with DESs and CABG are associated with a comparable risk of all-cause death, myocardial infarction, or stroke at long-term follow-up. Cumulative Kaplan-Meier curve reconstruction did not show significant differences over time, and long-term safety was acceptable with both PCI and CABG. The risk of repeat revascularization is the most important difference between techniques, with a higher risk for PCI at long-term follow-up compared with CABG. The use of first-generation DESs has been traditionally considered one of the explanations for the differential effectiveness between PCI and CABG in early randomized trials. In this respect in the EXCEL and NOBLE trials, 7, 8 patients who underwent PCI were treated with new-generation DESs. However, in our analysis, neither the risk of repeat revascularization nor the risk of the primary end point between techniques was influenced by DES generation. Considering the large amount of evidence supporting the superior antirestenotic properties of second-generation DESs compared with first-generation DESs, 25,35-37 it might be speculated that the superiority of CABG in this respect is driven by protection against the need for further revascularization in lesions outside the treated segment. In the EXCEL and NOBLE trials, 7,8 a several-fold increased risk of revascularization outside the target lesion was observed with PCI compared with CABG.
We performed a sensitivity analysis for the primary end point including only patients with low to intermediate complexity of CAD (according to the SYNTAX score 20 ) without detecting significant variations in treatment effects. In the SYNTAX trial, 26 the stratification of patients with LMCA stenosis according to SYNTAX score terciles showed significant differences in the primary outcome. However, in the PRE-COMBAT and EXCEL trials, 7 ,21 the largest number of events occurred in tercile 23 to 32 and there were no significant differences across terciles; however, in the NOBLE trial 8 the distribution of events was higher in the first tercile. These findings may reflect limitations of the anatomic SYNTAX score and support the use of tools also accounting for clinical characteristics. 39 The risk of issues arising relating to revascularization completeness, arterial grafting, and off-pump surgery is presented in eAppendix 2 in the Supplement. The risk of all-cause death and cardiac death between the techniques was similar at long-term follow-up. However, although the risks of myocardial infarction and stroke were also similar, we observed numeric variations between the techniques that are both likely attributable to heterogeneity introduced by the NOBLE trial. 8 With respect to myocardial infarction in the NOBLE trial, 8 there was a substantial risk increase with PCI. This finding can be partially explained by the definition of myocardial infarction used in the trial 8 that excluded periprocedural events, which generally are more frequent in patients undergoing CABG than PCI and sometimes large enough to be prognostically relevant over the long term. Moreover, although the incidence of periproce- dural myocardial infarction between PCI and CABG in the NOBLE trial 8 seemed comparable, data were collected in only approximately half of the patients. However, as observed in the SYNTAX trial, 30 a numeric increase in myocardial infarction may be partially explained by a possible superior protection of grafts against ischemic events due to CAD progression in nontarget lesions and a possible increase in periprocedural events in the higher number of patients requiring repeat revascularization after PCI. Similarly, with respect to stroke, the risk between techniques was reduced or comparable in all but the NOBLE trial, 8 in which an unexpected numeric increase in events occurred after PCI. The reason for the heterogeneity introduced by the NOBLE trial 8 is unclear. The main clinical, angiographic, and procedural characteristics of patients enrolled in the NOBLE trial 8 were overall comparable to or even more favorable for PCI (eg, 15% patients with diabetes, 91.7% completeness of revascularization, and 74% poststenting intravascular ultrasonography) than in other trials. Percutaneous coronary intervention presents a higher risk of a composite end point of major adverse cardiac and cerebrovascular events, including repeat revascularization, compared with CABG as a consequence of the significant excess in repeat revascularization. Trial design should take into account the prominent impact of repeat revascularization in driving differences in this end point. Moreover, it is likely inadvisable in this setting to combine safety end points (ie, all-cause death, myocardial infarction, or stroke) with an efficacy end point (ie, repeat revascularization). In patients with LMCA stenosis undergoing PCI or CABG, the importance of end point and estimator selection has been recently highlighted in the DrugEluting Stent for Left Main Coronary Artery Disease registry. 40 After assessing the evidence according to GRADE, we found high-quality evidence both with respect to the primary composite end point and repeat revascularization and moderate quality of evidence for death. However, evidence quality for myocardial infarction, stroke, and stent or graft occlusion was low, and caution must be exercised in interpreting the observations in relationship to these end points. Qualitative assessment of trials according to the Cochrane Collaboration tool showed an overall low risk of bias. Nevertheless, differences in patient characteristics and study definitions may have contributed to the variations in treatment effects seen.
Figure 3. Secondary End Point of Repeat Revascularization
Finally, we undertook additional analyses including randomized clinical trials comparing PCI with CABG in patients with MV-CAD without LMCA involvement to provide a comprehensive overview of long-term safety of PCI vs CABG. We observed significant between-group differences in the primary end point, with a higher risk of events with PCI compared with CABG in patients with MV-CAD and a borderline increased risk for all-cause death and myocardial infarction. These findings support the considerable influence of the pattern of CAD on treatment effects. Beyond unmeasured clinical differences between patients with the 2 CAD patterns, the difference in treatment effects may be related to several complementary factors, such as the larger reference vessel diameter of diseased coronary segments in the LMCA stenosis subset and the more diffuse extent of CAD in the MV-CAD sub- 
HR (95% CI)
The risk of all-cause death (A) and cardiac death (B) was comparable between patients randomized to percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG). The risk of myocardial infarction (C) tended to be higher in patients randomized to PCI, but the difference was nonsignificant compared with the risk in patients assigned to CABG and was mainly driven by the Nordic-Baltic-British Left Main Revascularisation (NOBLE) trial. 8 The risk of stroke (D) was numerically lower in patients randomized to PCI, but the difference was nonsignificant and attenuated by the NOBLE trial. set. Against this, the similar pooled risks of stroke in the LMCA stenosis and MV-CAD groups are likely explained by the close relationship of events with procedural invasiveness rather than CAD disease pattern.
In aggregate, these findings suggest that, in patients with significant stenosis of the LMCA and predominantly low to intermediate CAD complexity, both PCI and CABG are valid approaches to revascularization. Patient preference should be taken into consideration regarding the risks of periprocedural complications of surgery and long-term repeat revascularization after PCI. Patients with low surgical risk may benefit from CABG owing to more sustained effectiveness as evidenced by the reduced incidence of repeat revascularization. However, if a patient is not a good candidate for surgery or wishes to avoid the morbidity associated with surgical revascularization, PCI is a safe and effective alternative.
Limitations
Our study has some limitations. First, the absence of individual patient data and partial disclosure of results in original publications did not permit us to stratify patients according to every SYNTAX score tercile, perform additional subgroup analyses, and explore the impact of technical aspects of PCI procedures both in terms of the number of stents implanted to treat LMCA bifurcation (1 or 2 stents) and technique performed (eg, culotte, V-stenting, T and protrusion, crush, and double kissing crush). 41 In addition, although the use of intravascular imaging guidance has been associated with higher event-free survival after LMCA stenting, 42 data on this issue
are not uniformly available across trials. Second, in this metaanalysis, the SYNTAX trial 26,28-30,32 was considered as 2 cohorts. However, the randomization process was stratified according to the presence or absence of LMCA stenosis. Third, in the PRECOMBAT trial, 21 the composite end point included ischemia-driven target vessel revascularization instead of repeat revascularization as in the other trials. Fourth, in the NOBLE trial 8 during early enrollment, 11% of patients in the PCI group received first-generation DESs. Fifth, available follow-up in the EXCEL trial 7 was 3 years, while data from the other trials were from 5-year analyses. Although the effect on pooled estimate of possible effect size variation is expected to be limited, the results of the EXCEL trial 7 at 5 years may significantly change. In addition, fewer than half of the patients enrolled in the NOBLE trial 8 reached the 5-year follow-up, which reduces the precision of estimated cumulative incidences. Finally, the absence of significant differences between PCI and CABG in terms of all-cause death, myocardial infarction, or stroke may be due to lack of statistical power. All of the included trials have a noninferiority design-some with large margins and computations made for composite end point, including also repeat revascularization. Even after pooling the data, the total number of patients was not large enough for superiority testing.
Conclusions
In patients undergoing revascularization of LMCA stenosis, the PCI and CABG techniques are associated with a comparable risk of a composite of all-cause death, myocardial infarction, or stroke at long-term follow-up. However, patients treated with PCI present a higher risk of repeat revascularization compared with those who undergo CABG. Evidence quality with respect to both of these end points was high. Risk of deathboth all-cause and cardiac-was comparable between the 2 strategies, and only numeric differences in myocardial infarction and stroke were observed. 
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METHODS
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Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
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Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
Information sources 7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
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Supplementary Appendix Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
Supplementary Appendix
Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta analysis).
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Data collection process 10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
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Data items 11
List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
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Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
10-11,
Supplementary Appendix Summary measures 13 State the principal summary measures (e.g., risk ratio, difference in means).
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Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I
2 ) for each meta analysis.
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Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
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Study selection 17
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Study characteristics 18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. Tables   Supplementary  Appendix   Risk of bias  within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).
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Results of individual studies 20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. 
DISCUSSION
Summary of evidence 24
Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
16-20
Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
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Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for future research. Previous PCI or CABG; acute myocardial infarction with creatinine kinase >2x upper limit of normal; need for concomitant cardiac surgery (valve reconstruction or replacement); inability to give informed consent due to mental condition, mental retardation, or language barrier; participation or planned participation in another cardiovascular clinical study before completion of 1 year follow up.
16-20
Scopus ( TITLE ABS KEY( left main ) OR TITLE ABS KEY( three vessel ) OR TITLE ABS KEY( multivessel ) AND TITLE ABS KEY( myocardial ) OR TITLE ABS KEY( coronary ) OR TITLE ABS KEY( artery ) AND TITLE ABS KEY( stent ) OR TITLE ABS KEY( drug eluting stent ) OR TITLE ABS KEY( des ) OR TITLE ABS KEY( percutaneous coronary intervention ) OR TITLE ABS KEY( pci ) OR
Previous PCI 1 year; previous CABG; intention to treat >1 totally occluded major epicardial vessel; acute myocardial infarction 1 week; ejection fraction <30%; cardiogenic shock; stroke 6 months; creatinine >2.0 mg/dL or dialysis dependence; severe hepatic dysfunction (transaminases >3 times the normal upper reference limit; gastrointestinal or genitourinary bleeding 3 months; major surgery 2 months; history of a bleeding diathesis or coagulopathy or refusal of blood transfusions; platelets <100,000 cells/mm 3 ; hemoglobin <10 g/dL; planned elective surgery requiring interruption of thienopyridines within 1 year after enrolment; intolerance to study medications or contrast agents; intravenous sirolimus use 1 year; pregnancy; comorbidity that may result in protocol non compliance; life expectancy <1 year.
Prior PCI of the LMCA; prior PCI of any non LMCA lesion 1 year; prior CABG; need for concomitant cardiac surgery; need for non cardiac surgery 1 year; intolerance to dual antiplatelet therapy for 1 year; LMCA lesion <50%; LMCA reference diameter <2.25 mm or >4.25 mm; SYNTAX score 33; any recent myocardial infarction with creatine kinase MB levels still elevated; presence of any clinical and anatomic condition(s) which leads the participating interventional cardiologist and/or cardiac surgeon to believe that clinical equipoise is not present; pregnancy or intention to became pregnant; non cardiac co morbidities life expectancy <3 years; vulnerable population who in the judgment of the investigator is unable to give informed consent for reasons Previous PCI or CABG; acute myocardial infarction with creatinine kinase >2x upper limit of normal; need for concomitant cardiac surgery (valve reconstruction or replacement); inability to give informed consent due to mental condition, mental retardation, or language barrier; participation or planned participation in another cardiovascular clinical study before completion of 1 year follow up.
PRECOMBAT
FREEDOM
Diabetes mellitus (Type 1 or Type 2), defined as either presence of classic symptoms of diabetes mellitus with unequivocal elevation of plasma glucose (2 hour post prandial or random of greater than 200 mg/dL (11mmol/L) or fasting plasma glucose elevation on more than one occasion of at least 126 mg/dL (7mmol/L); pharmacological or non pharmacological treatment for diabetes; angiographic evidence of MV CAD 70% in 2 major epicardial vessels and in 2 separate coronary artery territories (left anterior descending, left circumflex, right coronary artery amenable to either PCI with DES or CABG; indication for revascularization based upon symptoms of angina and/or objective evidence of myocardial ischemia.
Severe congestive heart failure as New York Heart Association (NYHA) class III or IV or pulmonary edema; prior CABG surgery; prior valve surgery; prior PCI with stent implantation 6 months; stroke 6 months; prior stroke occurred >6 months with Rankin Score >1; prior significant bleeding 6 months; in stent restenosis of a target vessel; 2 chronic total occlusions in major coronary territories; LMCA stenosis 50% diameter stenosis; acute ST elevation myocardial infarction (Q wave) 72 hours requiring revascularization; abnormal creatine kinase level >2 times the upper normal limit; abnormal creatine kinase MB level at study entry; planned simultaneous surgical procedure unrelated to coronary revascularization (e.g., valve repair/replacement, aneurysmectomy, carotid endarterectomy, or carotid stent); unsuitability either of CABG or PCI with DES because of a coexisting medical condition; significant leukopenia, neutropenia, thrombocytopenia, anemia, or known bleeding diathesis; intolerance to aspirin or both clopidogrel and ticlopidine; dementia with Mini Mental Status Examination (MMSE) <20; extra cardiac illness expected to limit survival to <5 years (e.g., oxygen dependent chronic obstructive pulmonary disease, active hepatitis, significant hepatic failure, or severe kidney disease); pregnancy; enrolment in another clinical trial; inability to attend required follow up visits. Data used in this meta analysis were exclusively from intention to treat analyses. For each analysis, trial level risk estimates were extracted from retrieved reports and, in isolated cases, back calculated from log rank test p value and observed events in the two groups 14, 16 .
eMethods. Detailed Methodology
Trial level clinical and angiographic characteristics were extracted for each trial. Extracted data were collected in specific electronic spreadsheets. Meta analysis feasibility and qualitative assessment of the included trials was performed before statistical analyses.
eFigure 1. Diagram Flow
Description of trials selection process and final inclusion for qualitative analysis and quantitative synthesis by meta analysis.
a Cumulative number of reports identified by application of algorithm used for each database.
b Cumulative number of reports and conference proceedings deriving from tangential exploration of major scientific website, relevant reviews and book chapters. Duplicates were removed and different reports referring to the same trials were considered as single and collected together.
The included trials showed overall a low risk of bias. The systematic absence of blinding of patient and personnel may have influenced results in all trials but the characteristics of the two techniques obviously made this limitation unavoidable. The cumulative risk of bias in trials including patients with LMCA stenosis is illustrated in the upper panel, while the cumulative risk of bias after addition of trials including patients with MV CAD without LMCA stenosis is illustrated in the medium panel. The lower panel shows the individual components of bias assessment in each trial.
In the NOBLE trial 6 some important variables and some significant cardiovascular outcomes were not collected or showed. The BEST trial 9 was concluded early due to slow enrolment making its conclusions underpowered. Five trials were financially supported by companies that in one have active involvement in data collection and analysis. Finally, some definitions such as myocardial infarction differed in some trials from the all the others.
In the FREEDOM trial 8 the description of random sequence generation and allocation concealment are almost missing, while some endpoints such as major adverse cardiovascular events as all cause death, myocardial infarction, stroke or repeat revascularization or the endpoint of repeat revascularization at 5 years, are not reported and overall the number of measured outcomes is limited as compared with the other trials. Finally, Kaplan Meier incidences were not accompanied by risk estimates as HR and 95% CI. 
